A. Cosenza

PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors

A. Ardizzoni, M. Tiseo, S. Buti, 2021, Tumori.

Widespread Nivolumab‐induced Enteropathy in a Long Responder Non–Small‐cell Lung Cancer Patient

M. Tiseo, F. Fornaroli, L. Gnetti, 2018, Clinical lung cancer.

Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: a case report

M. Tiseo, C. Lagrasta, L. Bottarelli, 2020, Translational lung cancer research.

Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.

M. Tiseo, S. Buti, A. Leonetti, 2020, Lung cancer.

Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab.

A. Ardizzoni, M. Tiseo, S. Buti, 2018, Immunotherapy.

From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC.

M. Tiseo, R. Danesi, S. Buti, 2019, Lung cancer.

Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature

M. Tiseo, S. Buti, A. Leonetti, 2021, Cancers.

Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study

M. Tiseo, B. Vincenzi, S. Buti, 2023, Cancer Immunology, Immunotherapy.